<DOC>
	<DOCNO>NCT00778141</DOCNO>
	<brief_summary>The objective study compare relative bioavailability metformin HC1 750 mg extended-release tablet ( Ranbaxy ) GlucophageÂ® XR 750 mg tablet ( Bristol Myers Squibb ) healthy , adult , subject non-fasting condition .</brief_summary>
	<brief_title>Bioequivalence Study Metformin HCl 750 mg XR Tablets Under Non Fasting Conditions</brief_title>
	<detailed_description>1 . Design : Single dose , randomize , two-period , two-treatment , two- sequence crossover study non-fasting condition compare equal dos test reference product . 2 . Interval dose period : At least one week 3 . Period confinement : From least 10.5 hour dose 36 hour blood collection period . Subjects return clinic subsequent blood collation . A total thirty six ( 36 ) subject enrol study ; 33 complete study .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . All subject select study least 18 year age . 2 . Each subject shall give general physical examination within 28 day initiation study . Such examination include , limited , blood pressure , general observation , history . 3 . Each female subject give serum pregnancy test part prestudy screen process . At end study , subject exit evaluation consist interim history , global evaluation , clinical laboratory measurement . 4 . Adequate blood urine sample obtain within 28 day begin first period end trial clinical laboratory measurement . 5 . Clinical laboratory measurement include hematology , clinical chemistry , urine analysis , HIV screening , Hepatitis B &amp; C , drug abuse scan 1 . Subjects significant recent history chronic alcohol consumption drug addiction ( past two year ) , serious gastrointestinal , renal , hepatic cardio vascular disease , tuberculosis , epilepsy , asthma ( past five year ) , diabetes , psychosis glaucoma eligible study . 2 . Subjects whose clinical laboratory test value outside reference range may retested discretion clinical investigator . If clinical value outside range retesting , subject eligible participate study unless clinical investigator deem result significant . 3 . Subjects history allergic response class drug test exclude study 4 . All subject urine staple assay presence drug abuse per clinical laboratory screening procedure dose period checkin . Subjects found urine concentration test drug allow participate . 5 . Subjects donate blood and/or plasma least thirty ( 30 ) day prior first dose study . 6 . Subjects take investigational drug within thirty ( 30 ) day prior first dose study allow participate 7 . Female subject pregnant , breastfeeding , likely become pregnant study allow participate . Female subject child bear potential must either abstain sexual intercourse use reliable barrier method ( e.g . condom ) contraception course study ( first dose last blood collation ) allow participate . Female subject use hormone contraceptive within 14 day dose implanted injected hormone contraceptive within 180 day dose allowed participate . 8 . All female subject screen pregnancy checkin study period . Subjects positive inconclusive result withdraw study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Bioequivalecne metformin HC1 750 mg extended-release tablet</keyword>
</DOC>